USANA Health Sciences (NYSE: USNA) reported Q2 EPS of $0.89, $0.19 better than the analyst estimate of $0.70. Revenue for the quarter came in at $238 million versus the consensus estimate of $231.14 million.

GUIDANCE:

USANA Health Sciences sees FY2023 EPS of $2.65-$3.30, versus the consensus of $3.02. USANA Health Sciences sees FY2023 revenue of $900-950 million, versus the consensus of $940.57 million.

For earnings history and earnings-related data on USANA Health Sciences (USNA) click here.